Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development
Reference number: GID-TA11414
Expected publication date:
This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic;
Semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]
The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is:
Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]
Details of the MTA process can be found within the health technology evaluation manual on our website.